The U.S. Food and Drug Administration is alerting health care professionals and patients not to use drug products intended to be sterile that were produced in an inadequately designed processing room and distributed by Promise Pharmacy due to lack of sterility assurance.
Quick Take
The FDA is warning healthcare providers and patients to stop using all sterile drug products distributed by Promise Pharmacy due to a lack of sterility assurance. The alert follows an investigation revealing that the medications were produced in an inadequately designed processing room, creating a significant risk of contamination.
Why It Matters
In the ophthalmic space, the use of sterile compounded medications—ranging from intravitreal injections to fortified drops—is common, and any compromise in sterility can lead to catastrophic outcomes like endophthalmitis. This alert underscores the critical importance of facility design and environmental controls in compounding pharmacies. Practitioners must remain vigilant about the regulatory status of their suppliers to prevent exposing patients to potentially non-sterile agents that could cause permanent vision loss or systemic infection.
Key Details
Practice Implications
Clinicians should immediately audit their inventory for any sterile medications labeled from Promise Pharmacy and discontinue their use. Patients who have recently been treated with these products should be closely monitored for signs of infection or adverse reactions, and any suspected issues should be reported to the FDA’s MedWatch program.
Who's Affected
What's Next
The FDA will continue to monitor the situation and may provide updates if the pharmacy addresses its processing deficiencies. Providers should look for further communication regarding potential recalls or specific instructions for the disposal of affected inventory.
AI-generated summary — always read the original source for full context
No comments yet. Be the first to share your thoughts.
